Hyperalphalipoproteinaemic activity of BRL 26314--II. Inhibition of atherosclerosis in rabbits.
Optimization of a combination of balloon catheter-induced aortic de-endothelialization with provision of a palatable atherogenic diet to rabbits leads to hyperbetalipoproteinaemia and atherosclerosis rather than to the cholesterol-storage disease which characterized earlier models. Administration of BRL 26314 [N-(4-chlorobenzyl)-L-phenylalanine] during the induction of atherosclerosis specifically raised high-density lipoprotein (HDL) and decreased the arterial content of cholesterol and collagen in association with reduction in severity of thoracic sudanophilic lesions and intimal-thickening. This anti-atherosclerotic activity was superior to that observed for various standard compounds, and the present studies, using BRL 26314 as a pharmacological tool, provide evidence in vivo for an association between the elevation of HDL and reduction of arterial disease.
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D004195:Disease Models, Animal; D006951:Hyperlipoproteinemias / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011817:Rabbits
D008075:Lipoproteins, HDL; D010649:Phenylalanine; C040508:BRL 26314; D002784:Cholesterol